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Abstract: In China, there are two categories of vaccines available from the Chinese Center for
Disease Control and associated public health agencies. Extended Program of Immunization (EPI)
vaccines are government-funded and non-EPI vaccines are voluntary and paid for out-of-pocket.
The government plans to transition some non-EPI vaccines to EPI in the coming years, which
may burden public health system capacity, particularly in terms of budget, workforce, supply
chains, and information systems. Our study explored vaccinator and caregiver perspectives on
introducing non-EPI vaccines into routine immunization and perceived facilitators and barriers
affecting this transition. We conducted a qualitative study from a realist perspective, analysing semi-
structured interviews with 26 vaccination providers and 160 caregivers in three provinces, selected to
represent regional socioeconomic disparities across Eastern, Central, and Western China. Data were
analysed thematically, using deductive and inductive coding. Most participants were positive about
adding vaccines to the national schedule. Candidate EPI vaccines most frequently recommended
by participants were varicella, mumps vaccine, and hand–foot–mouth disease. Providers generally
considered existing workspaces, cold-chain equipment, and funding sufficient, but described frontline
staffing and vaccine information systems as requiring improvement. This is the first qualitative study
to explore interest, barriers, and facilitators related to adding vaccines to China’s national schedule
from provider and caregiver perspectives. Findings can inform government efforts to introduce
additional vaccines, by including efforts to retain and recruit vaccine programme staff and implement
whole-process data management and health information systems that allow unified nationwide data
collection and sharing.
Keywords: vaccination; routine immunization; health systems; barriers and facilitators; China
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1. Introduction
The Chinese government has promoted childhood vaccination since the 1950s [1],
adopting a “prevention first” principle into health policy and implementing countrywide
vaccination against vaccinia (smallpox). In 1978, China initiated its Expanded Program on
Immunization (EPI) [2], providing Bacillus Calmette-Guerin (BCG), Diphtheria, Pertussis,
Tetanus (DPT), polio, and measles vaccines as “4 vaccines against 6 vaccine-preventable
diseases” [3]. In 2007, the government expanded national provision to “14 vaccines against
15 vaccine-preventable diseases” [4]. It is now considering incorporating additional vac-
cines, including the hand, foot, and mouth disease (EV71) vaccine and the pneumococcal
conjugate vaccine (PCV).
The Chinese public health system, responsible for immunization, is a five-tiered system
from central to township level. It consists primarily of the National Health Commission
(China’s Ministry of Health equivalent) and subordinate bodies, the Chinese Center for
Disease Control and Prevention (CDC) and subordinate bodies, township health centres in
rural areas, and community health centres in urban areas. The system currently delivers
two types of vaccines; EPI vaccines are paid for by the fiscal budget and non-EPI vaccines
are voluntary and paid for out-of-pocket by recipients. EPI and non-EPI vaccines are
both distributed through public vaccine supply chains run by the Chinese CDC and its
subordinate bodies. Table S1 shows vaccines provided in China as EPI or non-EPI. The
government’s plans to transition some non-EPI vaccines to the EPI schedule in the next few
years will increase the burden on the limited public health system capacity, particularly in
terms of budget, workforce, supply chains, and information systems.
Research on the potential effects of expanding China’s EPI schedule includes studies
on the effects of introducing MMR and hepatitis A vaccines on mumps [5] and hepati-
tis A antibody levels [6], respectively, influencing factors, such as disease burden [7],
cost-effectiveness of vaccine introduction [8,9], vaccine safety and effectiveness [10,11],
and international or national advocacy [12]. Other studies investigate cold chain equip-
ment [13] and personnel [14] capacities. However, authors found no qualitative studies
on provider or service-user perspectives of introducing non-EPI vaccines into the routine
schedule in China. Research in other countries has included providers’ attitudes and how
such considerations hindered the introduction of the dengue vaccine in Colombia and
Venezuela [15]. Thus, it is important to examine these perspectives on the capacity of the
Chinese public health system to deliver additional vaccines, while maintaining current
performance levels. Our study aimed to examine vaccinator and caregiver attitudes to
introducing non-EPI vaccines into routine immunization and perceived facilitators and
barriers affecting this transition.
2. Materials and Methods
2.1. Study Design
We adopted a qualitative study design, using a realist approach as described by
Maxwell [16], which included semi-structured interviews with vaccination providers and
caregivers in Guangdong, Henan, and Sichuan provinces. Realist approaches are common,
though often not explicit, in qualitative public health research, as they enable pragmatic
engagement with a ‘real world’, to which our concepts and theories refer, which remains a
powerful and resilient research stance in public health.
2.2. Research Question
Our primary research question was “What are vaccination provider perspectives on
the Chinese public health system capacity to deliver additional vaccines, such as EV71
vaccine and PCV?”
2.3. Study Sites
First, we purposively selected three provinces to represent regional socioeconomic
disparities across Eastern, Central, and Western China that could influence public health
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system capacity to deliver immunization services (see Table S2). Second, we randomly
selected 1 rural county and 1 urban district per province to account for China’s dichotomous
rural–urban service delivery structure. Third, we purposively selected 3–5 community
healthcare centres (i.e., vaccination facilities) in each of the 6 selected districts/counties,
and 1 local CDC in each province. Thus, 22 vaccination facilities and 3 district/county
CDCs were included in this study.
2.4. Participant Recruitment
To obtain a range of perspectives, we purposively sampled and recruited an EPI
manager or senior immunization staff at each of the 22 vaccination facilities and 3 dis-
trict/county CDCs. At each vaccination facility, we similarly purposively recruited approx-
imately 5 caregivers in waiting rooms after their children were vaccinated. To account for
non-attendees, we additionally recruited approximately 3 caregivers per facility catchment
community, through a random sample of the vaccination register system (i.e., Immunization
Information System). This system includes information on children’s socio-demographics
(i.e., name, birthdate, birthplace), immunization record (i.e., type, dose, date), and caregiver
information (i.e., name, phone number) for use in sending vaccination reminders. In total,
we interviewed 26 providers and 160 caregivers.
2.5. Data Collection
We conducted interviews April–July 2019, using interview guides pre-tested in Shang-
hai (i.e., at 1 rural and 1 urban public facility, 2 corresponding district/county CDCs, and
Shanghai CDC). Provider topics included interest in and feasibility of including new vac-
cines, challenges, and enablers of converting vaccines from private-sector to public-sector
delivery, and vaccination experiences. Caregiver topics included interest in additional
public vaccines, any known barriers and enablers, and vaccination experiences.
All interviews were conducted face-to-face in Mandarin by one of 7 trained interview-
ers, after written informed consent was obtained. Consent consisted of an interviewer
introduction to the purpose, aims, topics, and ethics of the study, discussing participa-
tion, and answering any questions. Provider interviews lasted approximately 45 min and
caregiver interviews lasted about 25 min. Interviews were audio recorded and investiga-
tors also compiled field notes on the interview environment, interviewee body language,
self-reflection, and other relevant information, which was used to inform analysis. As
caregivers did not contribute to barriers or facilitators, their views are only reported under
willingness and acceptability.
2.6. Analysis
We transcribed audio files verbatim in Mandarin and entered transcripts into the
NVivo 11 (QSR International Pty Ltd., Victoria, Australia) data management software and
used Braun and Clarke’s six-stage thematic analysis approach [17]. First, three investiga-
tors (i.e., MS, DG, JC) read and became familiarised with the data. Second, investigators
independently generated initial codes. Third, investigators developed a coding structure
iteratively, collating codes related to interest, barriers, and facilitators into preliminary
themes, which was translated into English for discussion with non-Mandarin fluent co-
authors. Investigators examined relationships between codes, focusing on the research
question, compiled them, and summarised the content of each theme. This summary was
translated into English for inputs from non-Mandarin fluent co-authors. Fourth, investiga-
tors conducted thematic mapping. Fifth, investigators refined and defined independent
themes through discussion and further integration. Finally, all investigators reviewed and
refined themes during the reporting process. To protect participant privacy and anonymity,
we assigned identification codes (i.e., “P#” for providers, “C#” for caregivers).
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3. Results
3.1. Participant Characteristics
Table 1 provides the socio-demographic characteristics of participants. The 26 providers
(i.e., 18 EPI managers and 5 vaccinators from vaccination facilities, 3 CDC EPI managers)
were from Sichuan (38.5%), Henan (34.6%), and Guangdong (26.9%) provinces. The average
age was 42.5 and approximately 46.2% had vocational college training or below, mainly in
nursing (42.3%) and preventive medicine (23.1%). Of the 160 caregivers, we interviewed 94
at vaccination facilities and 66 through vaccination registers. Caregivers were from Sichuan
(26.9%), Henan (31.9%), and Guangdong (41.2%) provinces. Approximately 79.4% were
women, and all were parents of a vaccinated child. The average age was 35 years old and
15.0% had vocational college training or above (vocational college provides post-secondary
vocational training rather than a bachelor’s degree).
Table 1. Participant characteristics.














Below vocational college 6 (23.1)
Vocational college 6 (23.1)
Undergraduate 5 (19.2)
Masters 1 (3.8)
Missing 8 (30.8) *
Major
Clinical medicine 5 (19.2)
Nursing 11 (42.3)
Preventive medicine 6 (23.1)
Sanitary inspection 1 (3.8)
Chinese medicine 1 (3.8)
Missing 2 (7.7) *
Personnel category
CDC EPI manager 3 (11.5)
EPI manager 18 (69.3)
Vaccinator 5 (19.2)















Below vocational college 34 (21.3)
Vocational college 10 (6.3)
Undergraduate 13 (8.1)
Master 1 (0.6)
Missing 102 (63.7) *
Source of respondents
Vaccination facilities 94 (58.8)




Note: * Some participants were unwilling to disclose personal information.
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3.2. Analytical Themes
We describe findings below under willingness and acceptability, barriers (i.e., work-
force and workload; information systems), and facilitators (i.e., workspace and equipment;
funding; previous experience).
3.2.1. Willingness and Acceptability
Providers
Most participants said they welcomed moves to transition non-EPI vaccines into the
national schedule. Primarily, they suggested it could reduce the burden of explaining non-
EPI vaccines to caregivers. As non-EPI vaccines required payment and were sometimes
very expensive, parents consulted providers about vaccine efficacy, safety, and price before
vaccination. Secondly, vaccine availability through EPI would attract more parents and
vaccination rates would likely improve. As one vaccinator noted:
“We certainly welcome it! We could reduce the communication time with parents
and would not need to emphasize the cost, so the burden would be much smaller.”
(P8)
The candidate EPI vaccines most frequently recommended by participants were the
varicella vaccine, the mumps vaccine, the hand, foot and mouth disease (HFMD) vaccine,
the influenza vaccine, and the 13-valent pneumonia vaccine (while MMR vaccination
was provided through EPI, a mumps-only vaccination was not). The first three were
well-known and commonly requested, as these viruses could cause epidemics through
public interactions in social places such as schools, while the latter two prevented seasonal
infections such as influenza. As one EPI manager suggested:
“Chickenpox, mumps [...]. These are infectious diseases. There are many children
in the school. Once there is an outbreak, it will be very serious. So, I think these
two vaccines are very important.” (P11)
Caregivers
Most caregivers said that they would support the transition of non-EPI vaccines to
EPI delivery, primarily because it would reduce their financial burden and because they
suggested that the safety of EPI vaccines was better guaranteed. Caregivers suggested that
they would be willing to accept longer waiting times if there was an increase in the number
of people attending facilities for vaccination. As one caregiver noted:
“Maybe after some [non-EPI] vaccines become free, more people would come to
vaccinate, and the waiting time would also become longer, but it is acceptable.”
(C21)
Most caregivers reported that their children had received non-EPI out-of-pocket
vaccines, indicating both a strong demand for childhood vaccinations and a presumption
that EPI vaccines were insufficient. The three preferred non-EPI vaccines recommended
by caregivers for transition were for chickenpox, HFMD, and mumps, reportedly because
children were particularly vulnerable to these diseases. As one caregiver noted:
“I think chickenpox vaccine is necessary, because every child may experience it.
[If infected] the child will be very uncomfortable and it will be troublesome to
deal with it. And I also hope the flu vaccine [can become an EPI vaccine]...”(C32)
3.2.2. Workforce and Workload Barriers
Most providers suggested that vaccination staff numbers were insufficient, especially
in regard to young people with public health training and staff with vaccination licenses.
They noted it was difficult to recruit people to prevention and healthcare departments,
due to low wages and the perceived low value of the positions. Most suggested more staff
would be needed if additional vaccines were added to the national schedule. As a provider
from Guangdong province observed:
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“There are 13 staff in our department, only three of them are full-time in immu-
nization planning. Others have part-time jobs, such as prevention and control
of infectious diseases and chronic diseases, and health supervision and manage-
ment. So, the lack of staff is a big problem. Moreover, many young staff are
temporary workers and it is very difficult to become regular employees, which
led to their resignations.”(P20)
Some providers suggested that an increase in the rotation of existing staff could solve
staff shortages. As a provider from Henan explained, when asked about additional vaccines:
“There is no need to increase the number of staff. The four of us could take turns
to arrange shifts and complete the work.” (P5)
As vaccination facilities had different vaccinator numbers, workspaces, and cold
storage capacities, daily vaccination volumes in each facility varied between approximately
50 and 270 injections. Most providers indicated that an increase in vaccination volume of
10–50% would be acceptable, considering current space, staff, and cold storage capacities.
However, if vaccination volumes doubled, vaccination rooms would become crowded,
while staff and cold storage capacity would be insufficient. A few providers in Guangdong
province suggested current vaccination volumes were at upper limits:
“270 injections a day has been a lot [...]. Maybe it can be increased by about 10%
to about 50%, and no more can be sustained.” (P22)
3.2.3. Information System Barriers
Most providers suggested that the current vaccination information system was imper-
fect. For example, electronic calling was not popular and information systems were not
interconnected nationwide. One provider noted particular challenges relating to mobility:
“Immunization Information Systems can be connected within the city, but not
within the province, and not among the provinces. There are so many migrant
people in our district. It’s a problem because migrant people have been vaccinated
in other places, but you can’t download this information when he comes here.”
(P20)
Appointment setting was primarily traditional, using reservation books and oral
notification. Few providers used apps, such as “Xiao Doumiao” and WeChat official, due
to insufficient promotion and glitches in service functions. As a facility manager observed:
“Very few people use it [apps] now. We used to teach caregivers, but now we
can’t teach too many people. Because we are only four people. We are too busy.”
(P25)
3.2.4. Workspace and Equipment as Facilitators
Most providers indicated they had sufficient workspace, though a few said their
workspace did not meet standards and some did not have observation space for adverse
events following immunization (AEFIs). One Guangdong provider described:
“[Facilities in] Guangdong Province are divided by stars, from one-star to five-
star. We can only achieve three-star. Some infrastructure are not up to standard.
For example, there is no special room for AEFIs.” (P20)
Providers suggested that current space was sufficient if vaccination volume increased
by 30–50%; for example, if 1–2 non-EPI vaccines were transitioned to the national schedule.
However, if vaccination volumes more than doubled, they would not have capacity. As a
Henan provider observed:
“At present—when there are 60–70 recipients per day—there will be no crowding,
because everyone conscientiously queues up. But if a new EPI vaccine is added,
the space will start to crowd at 100 recipients per day.” (P1)
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Most providers reported their current cold storage capacity as sufficient, with some
spare that could accommodate 1–2 new EPI vaccines. Only three providers indicated no
spare cold storage capacity at their facility. If non-EPI vaccines transferred to EPI vaccines,
others suggested that, either way, they could apply for additional cold storage equipment:
“It [cold storage space] could be enough. If not, we can apply for new refrigerators
from the department of health...” (P9)
3.2.5. Funding as Facilitator
Current national vaccination schedule funding is allocated by the government, with
only a few providers suggesting it was insufficient or difficult to apply for electronic
equipment upgrades. As a facility manager from Guangdong said:
“The funds are provided by the district government and our institutional funds
are sufficient. All the money we collect will be handed over to the district
government, which will then allocate us funds.” (P21)
Most providers indicated that adding additional vaccines to the national schedule
would likely have little effect on their facility’s capital allocation or salaries, though they
hoped it would increase salary funding.
“We only provide vaccination services. As for funding, the government will
guarantee it.”(P17)
3.2.6. Previous Experience as Facilitator
All providers said their experience of the polio vaccine changing from oral to injection
on the national schedule had minimal impact on their workload. Several suggested that it
was more convenient to provide injected than oral vaccines to children. As a Guangdong
provider explained:
“In fact, I would rather offer injections than ‘sugar pills’. Because some babies
are too young, I need to prepare water cups and boiling water, and use a spoon
to break the ‘sugar pills’ before feeding them, which is too troublesome!” (P26)
4. Discussion
This qualitative study explored providers’ interest, barriers, and facilitators to, and
caregivers’ willingness and acceptability of, delivering additional vaccines through the
national EPI schedule. Such frontline perspectives are important and can help inform
policy development. Our study indicated providers and caregivers were positive about
including additional vaccines in the national schedule, and providers expected existing
workspaces, cold chain equipment, and funding could meet demands for 1–2 additional
EPI vaccines, which differs from findings in other middle-income countries where financing
is a major barrier [15,18]. Several possible explanations for these differences exist. First, the
Chinese government has routinely prioritised the national immunization programme and
allocated it specific funding (e.g., vaccination funding per person was ensured through
the 2009 Essential Public Health Services guidance) [19]. Second, the government invested
significantly in infectious disease control through the CDC system, including workspaces
and cold chain equipment at vaccination facilities, after the 2002–2004 SARS crisis [20].
Third, the 2005 Regulation on the Administration of Circulation and Vaccination of Vac-
cines [21], which specifies standards for vaccination procedures, workspaces, equipment,
and facilities, is strictly regulated. This enabled major improvements in vaccination facili-
ties and provision, creating a strong foundation on which to introduce additional vaccines.
Fourth, the government has focused on training vaccination providers on vaccine adminis-
tration policies and procedures, through both domestic and international sessions [22–24],
which may have enhanced their interest in delivering additional vaccines through the
national schedule.
The main potential barriers described by providers were personnel shortages and
health information system weaknesses [25,26]. Experiences from HPV vaccine introduc-
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tions in low- and middle-income countries also indicated that insufficient infrastructure
(e.g., electronic databases) and human resources were the main barriers [27], though a
study of Hepatitis B vaccine introduction in Ethiopia did not describe human resources as
a challenge [28]. In China, increased public demand for vaccination, including self-funded
non-EPI vaccines, has increased vaccination facility workloads. At the same time, some
EPI staff have taken on additional responsibilities such as chronic and infectious disease
management [29,30]. Limited EPI salaries and promotion opportunities have reduced
its attractiveness as a career choice and increased vaccination facility staffing instability
and turnover [31]. Increasing vaccination workload by introducing additional vaccines,
without addressing staffing constraints, could lead to more serious personnel shortages.
Therefore, the government should initiate efforts to both retain and recruit EPI staff, using
financial and nonfinancial incentives (e.g., increased salaries, continuing education, career
development) [29,32].
Inadequate facility-level immunization information systems could affect the transi-
tion of additional vaccines into the national schedule. Although China is promoting the
construction of Immunization Information Systems (IISs) [33], several problems remain.
First, the information system does not effectively address whole-process vaccination man-
agement of appointments, registration, and AEFI recording. Second, most immunization
information cannot be shared between facilities, cities, and provinces [34], thus exacerbat-
ing delayed/missed and repeated vaccinations, particularly among migrant children [35].
To ensure additional vaccines do not create overwhelming EPI workloads and caregiver
confusion, the government must ensure IISs provide whole-process services and whole-
link management [36,37], with unified data collection and sharing standards that allow
cross-regional data exchange [38].
Limitations
Several study limitations should be considered. First, due to budget and time con-
straints, we included three representative provinces and findings should not be generalised
to all provinces or districts in China. Second, while we included a range of provider levels,
we did not interview other key stakeholders, such as providers in other departments,
other ministries (e.g., finance), or vaccine manufacturers, who would likely have provided
different and additional perspectives.
5. Conclusions
This was the first qualitative study, of which authors are aware, to explore willingness,
barriers, and facilitators related to adding vaccines to China’s national schedule from
providers’ and caretakers’ perspectives. Most providers and caregivers supported the
transition of non-EPI vaccines to EPI delivery. We found that, based on current workloads
and previous experience, most providers were positive about adding new vaccines to the
national schedule and considered existing workspaces, cold-chain equipment, and funding
sufficient to meet the demands of 1–2 additional vaccines. However, frontline staffing and
information systems required improvement. Improvements, which could be implemented
before or alongside vaccine introductions, should include efforts to retain and recruit EPI
staff and implement a whole-process/whole-link health information system that allows
unified nationwide data collection and sharing standards.
Supplementary Materials: Available online at https://www.mdpi.com/article/10.3390/vaccines9
050476/s1, Table S1: EPI-provided and non-EPI vaccines available in China; Table S2: Main socio-
demographic indicators of study provinces in 2019.
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